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(that is, inhibitory IGF system components) and significantInsulin-like growth factor system components in hyperparathy-
positive correlations with IGFBP-3 and IGFBP-5 (that is, stim-roidism and renal osteodystrophy.
ulatory IGF system components). A positive correlation wasBackground. The insulin-like growth factor (IGF) system
observed between IGF-II and IGFBP-6. ESRF patients withplays a key role in regulation of bone formation. In patients
mixed uremic bone disease and histologic evidence for osteope-with renal osteodystrophy, an elevation of some IGF binding
proteins (IGFBPs) has been described, but there is no study nia revealed significantly (P , 0.05) higher levels of IGFBP-2
measuring serum levels of both IGF-I and IGF-II as well as and IGFBP-4 but lower IGFBP-5 levels. Histologic parameters
IGFBP-1 to -6 in different forms of renal osteodystrophy and of bone formation showed significant positive correlations with
hyperparathyroidism. serum levels of IGF-I, IGF-II, and IGFBP-5. In contrast,
Methods. In a cross-sectional study, we investigated 319 pa- IGFBP-2 and IGFBP-4 correlated positively with indices of
tients with mild (N 5 29), moderate (N 5 48), preuremic (N 5 bone loss. Moreover, dialysis patients with low bone turn-
37), and end-stage renal failure (ESRF; N 5 205). The ESRF over (N 5 24) showed significantly (P , 0.05) lower levels of
group was treated by hemodialysis (HD; N 5 148), peritoneal IGFBP-5, PTH, B-ALP, and OSC than patients with high bone
dialysis (PD; N 5 27), or renal transplantation (RTX; N 5 30). turnover.
As controls without renal failure, we recruited age-matched Conclusion. Patients with primary and secondary hyperpara-
healthy subjects (N 5 87) and patients with primary hyperpara- thyroidism showed lower levels of the putative stimulatory
thyroidism (pHPT; N 5 25). Serum levels of total and free IGFBP-5 but higher levels of IGFBP-1, -2, -3, and -6, whereas
IGF-I, IGF-II, IGFBP-1 to -6, and biochemical bone markers total IGF-I and IGF-II levels were not or only moderately
including intact parathyroid hormone (PTH), bone alkaline increased. The marked increase in serum levels of IGFBP-4
phosphatase (B-ALP), and osteocalcin (OSC) were measured appeared to be characteristic for chronic renal failure. IGFBP-5
by specific immunometric assays. IGF system components and correlated with biochemical markers and histologic indices of
bone markers were correlated with clinical and bone histologic bone formation in renal osteodystrophy patients and was not
findings. Mean values 6 sem are given. influenced by renal function. Therefore, IGFBP-5 may gain
Results. With declining renal function a significant increase significance as a serological marker for osteopenia and low
was measured for IGFBP-1 (range 7- to 14-fold), IGFBP-2 bone turnover in long-term dialysis patients.
(3- to 8-fold), IGFBP-3 (1.5- to 3-fold), IGFBP-4 (3- to 19-
fold), and IGFBP-6 (8- to 25-fold), whereas IGFBP-5 levels
tended to decrease (1.3- to 1.6-fold). In contrast, serum levels
of IGF-I, free IGF-I, and IGF-II remained constant in most Bone remodeling is regulated by systemic hormones
patients. Compared with renal failure patients, pHPT patients and locally produced factors acting in concert to maintain
showed a similar decline in IGFBP-5 levels and less elevated bone mass [1, 2]. Insulin-like growth factors (IGFs) arelevels of IGFBP-1 (3.5-fold), IGFBP-2 (2-fold), IGFBP-3 (1.2-
among the most important regulators of bone cell func-fold), and IGFBP-6 (4-fold) but no elevation of IGFBP-4 levels.
In all subjects, free and total IGF-I levels showed significant tion because of their abundance and their proven ana-
negative correlations with IGFBP-1, IGFBP-2, and IGFBP-4 bolic effects on the skeleton (decreasing collagen degra-
dation, increasing bone matrix deposition, and increasing
osteoblastic cell recruitment) [3, 4]. The key role of theKey words: osteopenia, low bone turnover, dialysis, uremic bone dis-
ease, end-stage renal failure. IGF system in the local regulation of bone formation is
demonstrated by the finding that approximately 50% of
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known to be the mediator of growth hormone action in system components may only be partially influenced by
various tissues, including bone, whereas the biological bone cell production, these studies suggest that circulat-
role of circulating IGF-II is unclear. Most of the circulat- ing levels of IGF-I and IGFBPs are significantly related
ing IGFs ($99%) are bound to six specific high-affinity to bone metabolism and thus may be used as bone
IGF binding proteins (IGFBPs), which modulate IGF markers.
action both in a positive and negative manner [5–7]. Although in the last two decades great progress has
IGFBP-3, the quantitatively predominant IGFBP in cir- been made concerning renal replacement therapy, renal
culation, is positively regulated by growth hormone and osteodystrophy is still of major clinical importance in
potentiates IGF action under most conditions. IGFBP-3 patients with chronic renal failure (CRF). When renal
has the unique property of being able to associate with function declines by 50%, the kidneys are no longer able
an acid-labile subunit (ALS) after IGF binding, thus to synthesize appropriate amounts of active metabolites
forming a 150 kd complex. This large complex raises the of vitamin D3, thus leading to the development of second-
plasma half-life of IGFs from few minutes to several ary hyperparathyroidism (sHPT) [18, 19]. In sHPT, bone
hours, as this complex is essentially limited to the intra- histologic findings include an increased bone resorption
vascular space. On the other hand, 20 to 30% of the caused by enhanced osteoclastic activity, as well as oste-
serum IGFs are found in small (45 kd) protein complexes oidosis and osteomalacia. For the diagnosis and differen-
that contain IGFBPs but not ALS. The low molecular tial therapy of the different forms of renal osteodystrophy,
weight IGF-IGFBP complexes can leave the intravascu- bone biopsy and biochemical markers of bone metabolism
lar space and are supposed to be the primary vehicle are well-established tools [20, 21]. In this cross-sectional
that allows circulating IGFs to reach extravascular tissue study, we tested the hypothesis of whether the measure-
binding sites [8]. IGFs are often coexpressed with ment of circulating IGF system components as putative
IGFBPs in various tissues (for example, liver, kidney, anabolic regulators of bone metabolism may shed new
bone), and circulating as well as locally expressed light on the complex pathophysiology of different forms
IGFBPs appear to modify IGF action by either inhibiting of hyperparathyroidism and renal osteodystrophy. Our
or promoting IGF bioactivity. In bone cells, locally pro- data clearly indicate an imbalance between serum levels
duced IGF system components may act as potential en- of IGFs and IGFBPs with declining renal function that
dogenous mediators of a variety of osteoregulatory may lead to a lower bioavailability of IGF-I to target
agents, including PTH and calcitriol, and may modulate tissues such as bone resulting in impairment of bone
IGF actions in both a positive (for example, IGFBP-5) formation. Concerning the IGF system components mea-
and negative manner (for example, IGFBP-4) [3, 4, 9, 10]. sured, in renal osteodystrophy, elevated IGFBP-4 and
In contrast to the well-defined local action of IGF-I
decreased IGFBP-5 levels may be particularly associated
on the skeleton, the relationship between circulating IGF
with osteopenia and low bone turnover (LTO).system components and bone remodeling is less well
understood. PTH infusion increased circulating levels
of IGFBP-3 in healthy women but not in patients with METHODS
inflammatory active rheumatoid arthritis. However, Patients
when inflammation had subsided, the patients responded
In this cross-sectional study, we investigated 319 pa-with a similar increase in IGFBP-3 levels as the control
tients with different stages of CRF from three hospitalsgroup [11]. In patients with idiopathic osteoporosis, de-
and four dialysis centers. As controls without renal fail-creased serum levels of IGFBP-3 have been reported
ure, we recruited age-matched healthy subjects (N 5 87)[12]. Another study showed that IGF-I serum levels
and patients with primary hyperparathyroidism (pHPT;showed a significant positive correlation with the osteo-
N 5 25). The study protocol was approved by the localblastic surface measured by histomorphometric tech-
ethics committee. All subjects gave informed consent toniques [13]. In insulin-dependent diabetes mellitus
participate in this study. Clinical and laboratory findings(IDDM) patients, it has been shown that low IGF-I and
are given in Table 1. The CRF group consisted of 29elevated IGFBP-1 levels contribute to impaired growth
subjects with mild, 48 with moderate, 37 with preuremic,in prepubertal subjects [14]. In IDDM patients, we re-
and 205 with end-stage renal failure (ESRF). The causecently observed that bone mineral density was positively
of renal failure included chronic glomerulonephritiscorrelated with stimulatory IGF system components
(N 5 93, 29%); interstitial nephropathy, including(IGF-I, IGFBP-3, and IGFBP-5) and negatively corre-
chronic pyelonephritis, obstructive uropathy, and vesi-lated with inhibitory IGF system components (IGFBP-1
coureteral reflux (N 5 54, 17%); hereditary nephropa-and IGFBP-4) [15]. In older women with hip and spine
thy, including polycystic kidney disease (N 5 44, 14%);fractures, increased IGFBP-4 serum levels have been
diabetic nephropathy (N 5 44, 14%); renovascular dis-reported, which were positively correlated to elevated
PTH concentrations [16, 17]. Although circulating IGF ease (N 5 30, 9%); analgesic nephropathy (N 5 10, 3%);
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Table 1. Clinical data and laboratory findings (reference values in parentheses) in patients with primary hyperparathyroidism (pHPT) and
different stages of chronic renal failure (CRF)
pHPT CRF I8 CRF II8 CRF III8 ESRF/HD ESRF/PD ESRF/RTX
N 25 29 48 37 148 27 30 (S 5 344)
Sex female/male 17/8 17/12 20/28 10/27 68/80 13/14 10/20
Age years 6063 5662.6 5662.6 5762.5 5663 4563a 4762a
[23–83] [21–79] [26–82] [20–82] [17–84] [21–75] [24–66]
Duration of CRF years — 3.160.6 5.961.2 6.960.8 7.460.6 9.461b 12.361.2bc
[0.3–13] [0.2–25] [0.2–21] [0.1–37] [1–33] [3–34]
Duration of HD, PD, or RTX years — — — — 4.460.4 5.260.5 7.060.6c
[0.1–20] [1–13] [2–16]
Creatinine 58–110 lmol/L 7865 16068a 359611a 675627a 692620a 898650a 263632abc
[60–108] [111–245] [226–540] [488–1114] [327–1353] [680–1541] [83–734]
Hemoglobin 12–15 g/dL 14.460.5 12.260.6a 11.460.3a 9.960.3a 9.860.2a 10.060.2a 12.160.4abc
[12–15.8] [11–15.3] [7.8–15.6] [7.3–14.6] [7–14.5] [7.5–13.2] [8.2–16.7]
PTH 11–54 pg/mL 193635 142630 303640a 374637a 345630a 309657a 273645ab
[79–950] [14–627] [14–1365] [69–1135] [2–1470] [6–1174] [21–1160]
B-ALP 7–17 ng/mL 20.764 27.4611 20.663 15.362 23.764 16.962 19.362
[4–68] [3–38] [3–63] [6–53] [4–353] [5–51] [5–424]
OSC 11–48 ng/mL 3966 4067 66 613a 161634a 185639a 186671a 137671a
[7–135] [4–115] [7–422] [8–958] [11–2280] [13–1602] [7–2244]
PICP 40–200 ng/mL 157616 173623 213622a 211625a 224615a 300628a 265658a
[55–439] [81–531] [53–660] [66–675] [66–1066] [76–587] [88–529]
25-D3 10–60 ng/mL 18.762 18.363 24.464 27.666 30.365a 15.663 18.162
[6–41] [2–50] [5–49] [4–52] [4–63] [5–25] [4–39]
1.25-D3 30–70 pg/mL 78.467 30.765a 17.562a 11.561a 12.961a 5.662ab 29.665abc
[22–138] [3–67] [5–31] [5–25] [0.6–50] [3–12] [1–56]
Data are mean values [range] 6 sem. Abbreviations are in the Appendix.
a P , 0.05 vs. pHPT
b P , 0.05 vs. CRF III8
c P , 0.05 vs. PD
multiple system disorders (N 5 10, 3%); and unknown the following parameters were assessed and graded ac-
cording to a four-point semiquantitative scale (22 5origin (N 5 34, 11%).
The stages of CRF were defined as follows: CRF I8, markedly decreased; 21 5 decreased; 0 5 normal, 1 5
increased): cortical bone thickness, trabecular bone vol-mild renal insufficiency with creatinine up to 250 mmol/L
and hyperparathyroidism but no further clinical signs of ume, trabecular thickness, trabecular interconnections,
osteoid thickness, endosteal fibrosis, osteoblastic surface,CRF; CRF II8, moderate renal insufficiency with serum
creatinine levels between 250 and 500 mmol/L and addi- osteoclastic surface, and bone marrow hematopoietic cell
volume. All measurements were performed blindly bytional signs of CRF such as incipient anemia or metabolic
acidosis; CRF III8, serum creatinine levels above 500 the same person without the knowledge of the corre-
sponding serum levels of bone markers and IGF systemmmol/L plus typical clinical manifestations of the com-
plex uremic syndrome (for example, metabolic acidosis, components.
Hemodialysis patients were routinely dialyzed four tofluid overload, electrolyte disturbances, accumulation of
end-products of protein metabolism). With end-stage five hours three times weekly (blood flow, 200 to 300 mL/
min; dialysate flow, 500 mL/min) using standard (N 5 87)renal failure (ESRF), patients were on maintenance re-
nal replacement therapy by bicarbonate hemodialysis or high-flux (N 5 61) HD membranes. For both HD
and PD, the dialysate calcium concentration was 1.75(HD; N 5 148), peritoneal dialysis (PD; N 5 27), or
renal transplantation (RTX; N 5 30). Six HD patients mmol/L. A lower dialysate calcium was used in patients
with low parathyroid hormone (PTH) levels and lowhad parathyroidectomy prior to the study.
In 28 HD patients, anterior iliac crest bone biopsies turnover osteopathy based on histologic diagnosis (N 5
16). Calcium carbonate or calcium acetate were usedwere performed under local anesthesia. Transcortical
bone samples of 2 to 3 cm in length and 5 mm in diameter as the primary phosphate binders. Moderate doses of
aluminum hydroxide were added to the regimen only ifwere obtained using an electric drill (Straumann, Cam-
bridge, MA, USA). Histologic analysis of Goldner- calcium carbonate or calcium acetate resulted in intoler-
ance or did not adequately control serum phosphorusstained sections was performed as previously described
[19, 21]. Separate sections were also stained with aurin- (.5.5 mg/dL). Aluminum concentration in blood was
monitored every year and was lower than 10 mg/L.tricarboxylic acid for the identification of aluminum on
mineralizing bone surfaces. Bone biopsies were analyzed Active vitamin D metabolites (calcitriol/alphacalcidol)
were given to all patients who showed no critical cal-qualitatively and semiquantitatively. In each bone biopsy,
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cium 3 phosphate product or no suppressed PTH (CRF coefficients of variation of less than 4 and 8% and no
I8, 1/2; CRF II8, 4/1; CRF III8, 10/3; HD, 90/27; PD, cross-reaction with other IGFBPs.
10/3; RTX, 8/4). All RTX patients received prednisolone, IGFBP-2 was measured by a specific RIA with intra-
cyclosporine A (adjusted to whole-blood concentrations assay and interassay coefficients of variation of less than
between 120 and 180 ng/mL), and azathioprine (between 9 and 8% and no cross-reaction with IGFBP-1, -3, -4,
50 and 150 mg/day, adjusted to blood cell count). One -5, and -6 (DSL).
RTX patient had been switched from cyclosporine to IGFBP-3 was determined by a specific RIA with intra-
tacrolimus. The other medications included antihyper- assay and interassay coefficients of variation of less than
tensive drugs, erythropoetin, iron, and insulin, as needed. 3.5 and 7.5% and no cross-reaction with other IGFBPs
(Mediagnost).Assays
IGFBP-4 and IGFBP-5 were measured by specific
In all subjects, blood samples were collected under RIAs as previously described [17, 26] with intra-assay
standardized nonfasting conditions and prior to dialysis and interassay coefficients of variation of less than 10%
(HD group). Samples were immediately centrifuged for and no cross-reaction with other IGFBPs.
10 minutes at 4000 3 g and then stored at 2208C until IGFBP-6 was determined by a specific RIA with intra-
the assays were performed. Serum creatinine, calcium, assay and interassay coefficients of variation of less than
and phosphate were measured by standard biochemical
11 and 10% and no cross-reaction with IGFBP-1, -2, -3,
methods. To assess bone metabolism, we determined by
-4, and -5 (DSL).radioimmunoassay (RIA): bone-specific alkaline phos-
phatase (B-ALP; Hybritech, Ko¨ln, Germany), osteo-
Western immunoblot analysis
calcin (OSC; CIS, Dreieich, Germany), type-I colla-
A 0.05 mL sample was diluted with 0.05 mL nonreduc-gen cross-linked carboxyterminal telopeptide (ICTP;
ing sodium dodecyl sulfate (SDS)-dissociation bufferPharmacia, Freiburg, Germany), and carboxyterminal
(0.125 mol/L Tris HCl, pH 6.8, 4% SDS, 20% glycerol)propeptide of type-I procollagen (PICP; Pharmacia,
and then loaded onto a 1.5 mm discontinuous SDS-poly-Freiburg, Germany). 25OHD3 and 1,25-(OH)2D3 were
acrylamide gel electrophoresis (SDS-PAGE), and elec-measured by specific RIAs (Incstar, Stillwater, MN,
trophoresed at 10 mA overnight through a 4% stackingUSA) with a less than 2.5% cross-reactivity to other
gel and a 10 to 20% gradient separating gel. Aftervitamin D metabolites. Intact PTH was measured within
one week using a chemiluminescence immunometric SDS-PAGE, the proteins were transferred to 0.45 mm
assay (Nichols, CA, USA) with intra-assay and inter- BA-S nitrocellulose membrane (Schleicher and Schuell,
assay coefficients of variation of less than 7%. Keene, NH, USA), as previously described [26]. Nitro-
The components of the IGF system were measured cellulose membranes were blocked for one hour with 5%
according to published protocols [17, 22–26]. The normal nonfat dry milk, incubated for one hour with IGFBP-4
range of IGF-I and IGFBP levels was obtained from 87 antiserum (1:2000 dilution), and then incubated for one
age- and sex-matched healthy blood donors [mean age, hour with horseradish peroxidase-conjugated rabbit anti-
57 6 3 (18 to 70) years; female/male, 43/44) who were guinea pig IgG (1:1000 dilution; Zymed Laboratories,
randomly recruited from the University Hospital Ulm. San Francisco, CA, USA). Antigen-antibody reactions
Insulin-like growth factor-I was measured by an were visualized using ECL chemiluminescence reagents,
IGFBP-blocked specific RIA (IGF-R20; Mediagnost, as recommended by the manufacturer (Amersham Life
Tuebingen, Germany) with a cross-reactivity to IGF-II Sciences, Arlington Heights, IL, USA).
of less than 0.05% and intra- and interassay coefficients
of variation of less than 4 and 8%. Statistical analysis
Free IGF-I levels were determined by a specific RIA
Statistics were computed using SPSS. Results are ex-(DSL, Frankfurt, Germany) with intra-assay and in-
pressed as mean 6 sem. Data were analyzed performingterassay coefficients of variation of less than 11%. There
a one-way analysis of variance (ANOVA), followed bywas no cross-reaction with IGF-II, insulin, proinsulin,
the Newman-Keuls test. The analysis was separated forand growth hormone.
the individual subgroups. Correlations between variablesInsulin-like growth factor-II was measured by a spe-
(Pearson’s correlation coefficient) were assessed usingcific RIA (DSL) with intra-assay and interassay coeffi-
univariate linear regression analysis. Analysis of covari-cients of variation of less than 7.5 and 10.5%. There
ance was performed to investigate the influence of age,was no cross-reaction with IGF-I, insulin, proinsulin, and
sex, creatinine, PTH, and CRF stages on IGFBP-4 andIGFBP-2, -3, -4, and -5.
IGFBP-5 levels. P , 0.05 was accepted as statisticallyIGFBP-1 was measured by enzyme immunoassay
(ELISA; Mediagnost) with intra-assay and interassay significant.
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Table 2. Serum levels of IGF-I, free IGF-I, IGF-II and IGFBP-1 to -6 in patients with different stages of chronic renal failure (CRF),
end-stage renal failure (ESRF) treated by hemodialysis (HD), peritoneal dialysis (PD) or renal transplantation (RTX) compared to
age-matched healthy control subjects (Controls) and patients with primary hyperparathyroidism (pHPT)
Controls pHPT CRF I8 CRF II8 CRF III8 ESRF/HD ESRF/PD ESRF/RTX
N (S 5 431) 87 25 29 48 37 148 27 30
Age years 5763 6063 5662.6 5662.6 5762.5 5663 4563 4762
IGF-I 135615 n.d. 99623 149625 123627 171666 n.d. n.d.
[45–288] [69–129]a [63–216] [48–231] [44–412]
Free IGF-I 2.761.3 4.160.7 4.260.8 2.960.3 3.660.5 2.960.3 2.260.6 4.760.8
[0.94–9.4] [0.2–13.7]a [0.3–17]a [0.2–9.1] [0.4–11.7] [0.2–17.8] [0.2–15.7] [0.2–19.7]ad
IGF-II 461637 n.d. 519646 517676 501648 9256228 n.d. n.d.
[324–582] [408–720] [354–774] [306–660] [432–1546]a
IGFBP-1 2.362.1 8.162.2 15.665 2564 2664 33.263 25.766 17.963
[0.1–17] [0.2–66]a [1–104]ab [2–91]ab [3–80]ab [0.9–172]ab [1–98]ab [1.4–60]ab
IGFBP-2 474621 907691 14286185 18476108 24916171 2914697 35616207 14286123
[121–1172] [290–1667]a [452–2771]a [873–3287]ab [908–4101]ab [984–6615]ab [793–5216]ab [428–2831]abd
IGFBP-3 30876230 38536192 46106431 51206406 52676457 52696221 972161695 53496553
[1140–4968] [2347–6519]a [1100–11734]a [1747–17817]a [1607–11355]a [1083–15758]a [2673–45120]abc [1257–14533]ad
IGFBP-4 396630 430634 12186227 19376207 23436245 45576410 760761546 14426146
[160–796] [185–872] [263–6364]ab [693–7559]ab [966–8878]ab [764–40749]abc [1165–36692]abc [433–3670]abd
IGFBP-5 454644 298621 313617 284619 320622 362661 315624 319621
[319–713] [113–493]a [149–500]a [131–763]a [151–773]a [84–662] [109–544]a [124–570]a
IGFBP-6 9965 367672 8916131 986683 1097654 1666679 24976142 755672
[41–198] [67–1313]a [201–2041]ab [185–2917]ab [645–1596]ab [316–6345]abc [1006–4240]abc [273–1474]abd
Data are mean values [range] 6 sem. n.d. is not determined.
a P , 0.05 vs. controls
b P , 0.05 vs. pHPT
c P , 0.05 vs. CRF III8
d P , 0.05 vs. PD
RESULTS in immunoreactive IGFBP-4 represents an increase in
both intact and fragmented forms of IGFBP-4. As shownInsulin-like growth factor system components in the
in Figure 2, in PD patients (lane 1), approximately 50%different patient groups
of circulating IGFBP-4 could be attributed to lower mo-Table 2 summarizes data on circulating IGF system
lecular weight fragments, whereas patients with CRF I8components in CRF patients compared with pHPT pa-
(lane 3) showed no fragments.tients and age-matched healthy control subjects. As
To assess whether or not dialysis may influence IGFBPshown in Figure 1, with declining renal function, there
levels, blood samples were drawn before and after HD. Inwas a significant increase in circulating IGFBP-1 (range
20 HD patients, no differences could be observed for7- to 14-fold), IGFBP-2 (3- to 8-fold), IGFBP-3 (1.5- to
IGFBP-3 [before/after (ng/mL), 2682 6 330/2686 6 288],3-fold), IGFBP-4 (3- to 19-fold), and IGFBP-6 (8- to
IGFBP-4 (2190 6 36/2272 6 53, respectively) and IGFBP-525-fold). Generally, the disturbances in circulating IGF
(253 6 29/299 6 42, respectively). Furthermore, theresystem components were most expressed in PD patients,
were also no significant differences in IGF system com-whereas in RTX patients, circulating IGF system compo-
ponents between HD patients treated with high- or low-nents tended to normalize. In pHPT patients, the eleva-
flux dialysis.tion of IGFBP-1 (3.5-fold), IGFBP-2 (2-fold), IGFBP-3
Univariate correlation analysis revealed that in all(1.2-fold), and IGFBP-6 (4-fold) was significantly lower
CRF patients, levels of free IGF-I correlated positively(P , 0.01) than in renal failure patients. HD patients
with IGFBP-3 (r 5 0.28, P , 0.05) and IGFBP-5 (r 5revealed twofold higher IGF-II levels than the other
0.44, P , 0.005) but negatively with IGFBP-1 (r 5 20.35,groups (P , 0.05). Compared with control subjects, 1.5-
P , 0.01), IGFBP-2 (r 5 20.31, P , 0.01) and IGFBP-4fold higher levels of free IGF-I were found in pHPT,
(r 5 20.28, P , 0.05). Similar correlations were obtainedCRF I8, and RTX patients.
with total IGF-I (data not shown). Figure 3 demonstratesIn contrast to other IGFBPs, IGFBP-5 levels were
the correlations between free IGF-I and IGFBP-4 (Fig.decreased (1.5-fold, P , 0.05) in all patient groups. In
3A) and IGFBP-5 (Fig. 3B) in the different groups ofaccordance with our previous findings [15], HD patients
renal failure patients. Positive correlations were foundwith diabetes mellitus (N 5 34) showed lower IGFBP-5
between free IGF-I levels and total IGF-I (r 5 0.4, P ,levels (270 6 16 ng/mL) than HD patients without diabe-
0.01) and between IGF-II and IGFBP-6 (r 5 0.4, P ,tes mellitus (317 6 10 ng/mL, P , 0.05). Interestingly,
0.01). Analysis of covariance showed that in CRF andonly renal failure patients showed increased IGFBP-4
levels. Immunoblot analysis revealed that the increase ESRF patients, the different stages of renal insufficiency
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Fig. 2. Immunoblot analysis of insulin-like
growth factor binding protein (IGFBP)-4 in
sera of CRF patients with different IGFBP-4
levels. Sera from patients with high (1), me-
dium (2), and low (3) IGFBP-4 values were
separated by SDS-PAGE, transferred to ni-
trocellulose, and then immunoblotted with
IGFBP-4 antiserum. The molecular weight
(kd) of marker proteins is shown on the left.
Intact IGFBP-4 (!) and IGFBP-4 fragments
(star) are indicated. Mean IGFBP-4 concen-
trations (ng/mL; pooled sera of 5 patients in
each group), determined by RIA, are 8400
(1), 1840 (2), and 620 (3).
correlate with the differences in IGFBP-4 levels (creati- Osteoblastic surface correlated positively with serum lev-
els of PTH, OSC, IGF-I, and IGFBP-5. A positive rela-nine vs. IGFBP-4, r 5 0.58, P , 0.001; Fig. 4), whereas
gender was of minor influence (male patients showed tionship was observed between osteoid thickness and
PICP levels. Cortical bone thickness correlated posi-25% higher IGFBP-4 levels than females, P , 0.05).
IGFBP-5 levels were influenced by age (r 5 20.23, P , tively with serum levels of OSC, IGF-II, IGFBP-3, and
IGFBP-5 (Fig. 5A). Trabecular bone volume showed a0.005) but not by creatinine levels, the stage of renal
insufficiency, gender, or PTH levels. Furthermore, positive relationship with IGFBP-5 levels (Fig. 5B) but
was negatively correlated with IGFBP-2. Trabecular in-IGFBP-2, -3, and -6 but not IGFBP-1 were significantly
(P , 0.05) positive correlated with creatinine levels. terconnections correlated positively with serum levels of
B-ALP, OSC, IGF-I, IGFBP-5 (Fig. 5C), and IGFBP-6.Only IGFBP-6 showed a weak positive correlation with
CRF duration (r 5 0.19, P , 0.05). A further positive correlation was obtained between the
osteoblastic surface and IGFBP-5 (Fig. 5D). In contrast,
Relationship between bone histology and IGF system IGFBP-4 correlated negatively with trabecular thickness
components in hemodialysis patients and interconnections (Fig. 5 E, F). Finally, the bone
marrow hematopoietic cell volume correlated positivelyIn 28 HD patients, bone histologic examination re-
vealed mixed uremic bone disease (osteitis fibrosa plus with IGF-I, IGF-II, and IGFBP-6 levels and negatively
with IGFBP-1 levels.osteomalacia) with (N 5 17) or without (N 5 11) os-
teopenia. In all cases, there were no signs of aluminum
Bone markers in CRF and pHPT patientsaccumulation. The osteopenic subgroup showed reduced
trabecular framework, thinning of trabecular elements, As shown in Table 1, with deteriorating renal function
PTH levels significantly increased but 1,25-D3 levels de-and disruption of trabecular continuity. Overall, os-
teopenic patients revealed significantly higher levels of creased (CRF I8 vs. other CRF/ESRF stages, P , 0.01).
In contrast to renal failure patients, pHPT patientsIGFBP-2 and IGFBP-4 but lower levels of IGFBP-5,
B-ALP, and OSC (Table 3). Significant correlations were showed elevated levels of both PTH and 1,25-D3, which
is consistent with the physiological effect of PTH to stim-observed between bone biopsy parameters, bone mark-
ers, and IGF system components (Table 4). As expected, ulate 1,25-D3 synthesis. Interestingly, B-ALP levels were
highest in CRF I8 patients and lowest in PD patients,there were positive correlations between endosteal fi-
brosis and osteoclastic surface on the one hand and se- which is consistent with previous reports showing a
higher incidence of low turnover osteopathy in PD pa-rum levels of PTH, B-ALP, and OSC on the other hand.
b
Fig. 1. Serum levels of insulin-like growth factor (IGF) system components (means 6 SEM) and putative effects of bone formation in patients
with different stages of chronic renal failure (CRF) and end-stage renal failure (ESRF) as compared with healthy controls and patients with
primary hyperparathyroidism (pHPT). Serum levels of free IGF-I and IGFBP-1 to -5 were measured by specific immunometric assays. The stages
of chronic renal failure (CRF) were defined as follows: CRF I8, mild renal insufficiency with creatinine up to 250 mmol/L and hyperparathyroidism
but no further clinical signs of chronic renal failure (N 5 29); CRF II8, moderate renal insufficiency with serum creatinine levels between 250 and
500 mmol/L and additional signs of chronic renal failure such as incipient anemia or metabolic acidosis (N 5 48); CRF III8, serum creatinine levels
above 500 mmol/L plus typical clinical manifestations of the complex uremic syndrome (for example, metabolic acidosis, fluid overload, electrolyte
disturbances, accumulation of end-products of protein metabolism, N 5 37); ESRF/HD 5 ESRF patients who were on maintenance renal
replacement therapy by hemodialysis (N 5 148).
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Fig. 4. Relationship between IGFBP-4 levels and serum creatinine in
patients with different stages of renal insufficiency 1 [(3) CRF I8, (m)
CRF II8, (d) CRF III8, (13) ESRF/HD, (s) ESRF/PD, (h) RTX]. The
stages of chronic renal failure (CRF) were defined as described in the
Methods section and in the legend to Figure 1. IGFBP-4 was measured
by specific RIA and showed a positive correlation with serum creatinine
(r 5 0.58, P , 0.001).
200 pg/mL together with elevated B-ALP levels indicate
high bone turnover (HTO), dialysis patients were di-
vided into corresponding subgroups. Twenty-four dial-
ysis patients matched the criteria of LTO, and 151
matched those of HTO. In 5 LTO patients and in 20 HTO
patients, the diagnosis was confirmed by bone biopsy. As
shown in Table 5, both groups showed similar clinical
Fig. 3. Relationship between free IGF-I levels and IGFBP-4 (A) or
data. LTO patients showed significantly lower levels ofIGFBP-5 (B) in patients with different stages of renal insufficiency [(3)
CRF I8, (m) CRF II8, (d) CRF III8, (13) ESRF/HD, (s) ESRF/PD, PTH, B-ALP, OSC, and IGFBP-5 than HTO patients.
(h) RTX]. The stages of chronic renal failure (CRF) were defined as
described in the Methods section and in the legend to Figure 1. Free
IGF-I and IGFBPs were measured by specific RIA. Normal ranges are DISCUSSION
indicated. Free IGF-I levels correlated negatively (r 5 20.28, P , 0.05)
with IGFBP-4 (A) and positively (r 5 0.44, P , 0.005) with IGFBP-5 Our study provides the first analysis, to our knowledge,
(B). of immunoreactive serum levels of free and total IGF-I,
IGF-II, and all six IGFBPs in a larger group of adult
subjects with different forms of hyperparathyroidism and
renal osteodystrophy. We demonstrated that with declin-tients. In contrast to B-ALP, levels of OSC and PICP
ing renal function, serum levels of all IGFBPs exceptmarkedly increased with renal insufficiency. This may
IGFBP-5 considerably increase, whereas in most pa-be due to the reduced renal clearance of both markers
tients, IGF-I/-II serum levels were either not or onlyand degraded fragments cross-reacting in the assays.
moderately elevated. Taking into account the increasedNevertheless, OSC and B-ALP showed significant posi-
half-life of IGFs in renal failure, normal serum levels oftive correlations with PTH levels in all groups (r $ 0.45,
IGFs may indicate a reduced production [25, 33–35]. InP , 0.005). The finding that PICP, a marker of bone
children with CRF, a decreased hepatic IGF synthesismatrix formation, was not increased in pHPT or CRF
and markedly increased IGFBP levels have already beenI8 patients may indicate a negative uncoupling of bone
demonstrated [33, 36, 37]. In advanced CRF, other cir-formation to resorption in these groups.
cumstances such as protein energy malnutrition and met-
IGF system components in dialysis patients with low abolic acidosis have already been demonstrated to re-
or high bone turnover duce local and circulating IGF-I levels [38, 39].
The discrepancy between IGFs and IGFBPs is uniqueBased on recent reports [27–32] that in dialysis pa-
to CRF, as in all other clinical situations studied theretients, PTH levels within the normal range together with
is an approximate 1:1 ratio of total IGF (IGF-1 plusnormal B-ALP levels are sensitive and specific (60 to
95%) in the diagnosis of LTO, whereas PTH levels . IGF-2) to IGFBPs. Previous studies demonstrated that
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Table 3. Clinical data and IGF system components of HD patients with mixed uremic bone disease
with or without histological signs of osteopenia
HD patients with mixed With osteopenia Without osteopenia
uremic bone disease N 5 17 N 5 11
Clinical data
Age years 5263 [28–74] 4865 [33–71]
Duration of CRF years 8.561.5 [1–28] 9.662.4 [0.5–25]
Duration of dialysis years 3.860.6 [0.5–8] 3.160.5 [0.8–5]
Creatinine 58–110 lmol/L 620660 [446–1120] 707684 [370–1153]
Bone markers
PTH 11–54 pg/mL 275661 [14–630] 3406113 [2–1290]
B-ALP 7–17 ng/mL 1162.1 [1–32] 2766.5 [8–81]b
OSC 11–48 ng/mL 3164.6 [9–83] 4868 [8–75]a
PICP 40–200 ng/mL 195620 [83–406] 232620 [92–357]
25-D3 10–60 ng/mL 1665 [3–60] 2264 [16–49]
IGF system components
Free IGF-I 0.94–9.4 ng/mL 2.1460.3 [0.2–2.5] 3.0360.3 [0.3–4.4]
IGF-I 45–288 ng/mL 163618 [44–286] 198633 [53–412]
IGF-II 324–582 ng/mL 907643 [580–1144] 937670 [422–1125]
IGFBP-1 0.1–17 ng/mL 2863.8 [11.8–64] 35610 [4–112]
IGFBP-2 121–1172 ng/mL 24846134 [1527–3616] 19466188 [1111–2970]a
IGFBP-3 1140–4968 ng/mL 45436695 [643–10779] 48626509 [1841–8428]
IGFBP-4 160–796 ng/mL 928862238 [3619–21365] 626161052 [1574–12616]a
IGFBP-5 319–713 ng/mL 268617 [137–344] 320633 [185–509]a
IGFBP-6 41–198 ng/mL 26736214 [794–3685] 27876411 [643–5229]
Data are mean values [range] 6 sem; reference values are in parentheses.
aP , 0.05, bP , 0.005
Table 4. Correlations between bone histologic parameters and laboratory findings
CBTh TBV TTh TIn OTh EF ObS OcS BMHCV
Bone markers
PTH 0.16 20.11 0.02 0.23 0.26 0.38a 0.30a 0.56b 0.10
B-ALP 0.20 0.26 0.30a 0.40a 0.20 0.32a 0.23 0.20 20.11
OSC 0.42a 0.23 0.18 0.49b 0.25 0.34a 0.33a 0.30a 0.16
PICP 0.22 0.13 0.12 0.14 0.47b 20.01 0.27 20.13 0.02
IGF system components
Free IGF-I 0.03 20.12 0.03 20.09 20.04 0.04 0.14 20.24 0.18
IGF-I 0.14 0.15 0.17 0.44a 0.11 20.01 0.30a 20.14 0.41a
IGF-II 0.35a 20.11 0.11 0.08 0.08 0.06 0.18 0.07 0.34a
IGFBP-1 20.15 0.29 0.06 20.22 20.10 20.09 20.18 0.12 20.51b
IGFBP-2 20.26 20.33a 20.27 20.41a 20.23 0.20 20.09 0.27 20.17
IGFBP-3 0.37a 0.12 20.22 0.05 20.02 20.15 0.18 20.01 20.10
IGFBP-4 20.15 20.22 20.52b 20.33a 20.22 20.12 0.23 20.43a 0.05
IGFBP-5 0.35a 0.35a 0.17 0.38a 0.14 0.16 0.34a 20.15 0.20
IGFBP-6 0.12 0.07 20.10 0.39a 20.02 0.08 0.11 0.07 0.58b
In 28 HD patients anterior iliac crest bone biopsies were performed using an electric drill. Transcortical bone samples of 2 to 3 cm in length and 5 mm in diameter
were obtained. From Goldner stained sections the following parameters were assessed and graded according to a 4-point semiquantitative scale (22 5 markedly
decreased, 21 5 decreased, 0 5 normal, 1 5 increased): cortical bone thickness (CBTh), trabecular bone volume (TBV), trabecular thickness (TTh), trabecular
interconnections (TIn), osteoid thickness (OTh), endosteal fibrosis (EF), osteoblastic surface (ObS), osteoclastic surface (OcS), and bone marrow hematopoietic cell
volume (BMHCV). Coefficients of correlations (r) are given.
a P , 0.05
b P , 0.005
in CRF, circulating IGFBP-1 and -2 are truly increased, IGFBP-6 showed the most dramatic increase in ESRF
patients. As demonstrated for IGFBP-4, immunoblotand those studies found no evidence that significant
amounts of these binding proteins are degraded by spe- analysis revealed an increase in both intact and frag-
mented forms. The increased serum levels of IGFBP-4cific proteases, whereas IGFBP-3 levels are overesti-
mated by RIA because of proteolytic fragments (low may represent an increase in IGFBP-4 production or
alterations in IGFBP-4 proteolysis [7, 41, 42]. Analysismolecular weight IGFBP-3 forms) with normal amounts
of intact IGFBP-3 [25, 33, 35–37, 40]. In our study, the of covariance revealed that IGFBP-4 levels are predomi-
nantly influenced by the stage of renal insufficiency.disturbances in the IGF system were more evident in
PD than HD patients, whereas after RTX, IGFBP levels However, the decrease in renal clearance may not totally
account for the increased IGFBP-4 levels because serumtended to normalize. Serum levels of IGFBP-4 and
Jehle et al: IGF in renal osteodystrophy and hyperparathyroidism432
Fig. 5. Relationship between bone histologic findings and IGFBP-4/-5 levels in 28 hemodialysis patients. IGFBP-5 levels correlated positively
with cortical bone thickness (A), trabecular bone volume (B), trabecular interconnections (C ), and osteoblastic surface (D). In contrast, IGFBP-4
was negatively associated with trabecular thickness (E) and interconnections (F ). Transcortical bone biopsies were performed at the iliac crest
and histologic parameters were classified as follows: markedly decreased (22), decreased (21), normal (0), and increased (1). IGFBPs were
measured by specific RIAs.
levels of IGFBP-5, which is of similar molecular weight, lower molecular weight than intact IGFBPs (for exam-
ple, 18 kd fragment of IGFBP-4; Fig. 2) [5–7, 18].were not increased in CRF patients. Thus, the mecha-
nisms that contribute to increased or diminished serum Our study is the first report, to our knowledge, on
serum levels of IGFBP-4 and -5 in a large number oflevels of low molecular weight IGFBPs in renal failure
remain currently unknown. Of particular interest to this adult patients with different stages of CRF. Both IGFBPs
are considered to be important regulators of bone celldiscussion is that the increase in the relative levels of
free low molecular weight IGFBPs in the serum of CRF function. In vitro studies have shown that IGFBP-4 is a
potent inhibitor of IGF actions on bone cells by pre-patients could inhibit IGF actions in the local tissues
because these IGFBPs can easily cross the vascular endo- venting IGFs from binding to their receptors [9], whereas
IGFBP-5 may exert anabolic effects on osteoblasts bythelium [8]. This may contribute to end-organ resistance
to growth hormone and IGF-I in uremia [33, 43]. The an IGF-independent mechanism involving IGFBP-5–
specific binding sites [44]. Although the exact functionalhypothesis that at least some of the circulating IGF inhib-
itors are of small molecular weight is supported by the role of serum IGFBP-4 and IGFBP-5 is not clear at
this time, increased IGFBP-4 serum levels have beenfinding that HD treatment temporarily increases bioac-
tivity of IGF-I [36]. Because we did not measure sig- reported in hip fracture patients with elevated serum
PTH levels [16]. Interestingly, our study demonstratednificant differences in circulating IGFBP-3 (44 kd),
IGFBP-4 (25 kd), and IGFBP-5 (29 kd) before and after lower IGFBP-5 but higher IGFBP-4 levels in renal osteo-
dystrophy patients with histologic signs of osteopeniaHD, as well as in patients treated with high- or low-flux
dialysis, the postulated IGF inhibitors should have a and lower IGFBP-5 levels in LTO patients. It might
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Table 5. Clinical data, bone markers, and IGF system components in hemodialysis patients with low (LTO) or high (HTO) bone turnover
LTO HTO
HD patients N 5 24 N 5 151
Clinical data
Age years 5763 [39–81] 5462 [28–81]
Duration of dialysis years 4.161 [1–18] 4.660.4 [1–21]
Diabetes mellitus % of patients 21 19
PD/HD % of patients 20/80 15/85
Creatinine 58–110 lmol/L 681630 [441–1072] 731625 [360–1541]
Bone markers
PTH 11–54 pg/mL 2763 [2–54] 390629 [62–1470]b
B-ALP 7–17 ng/mL 1163 [2–17] 2561 [4–353]a
OSC 11–48 ng/mL 3165 [10–94] 205635 [18–2874]a
PICP 40–200 ng/mL 179619 [76–323] 247612 [83–1066]
IGF system components
Free IGF-I 0.94–9.4 ng/mL 2.1760.7 [0.3–15.7] 2.6860.2 [0.3–17.8]
IGFBP-1 0.1–17 ng/mL 47611 [3–219] 3463 [1–157]
IGFBP-2 121–1172 ng/mL 27436269 [1438–5216] 2602681 [1125–6615]
IGFBP-3 1140–4968 ng/mL 48606458 [1561–11394] 62276385 [1083–45120]
IGFBP-4 160–796 ng/mL 585261513 [1807–36692] 49576425 [764–40749]
IGFBP-5 319–713 ng/mL 264620 [84–494] 31569 [101–662]a
IGFBP-6 41–198 ng/mL 21026144 [1210–3702] 2228682 [316–6059]
Data are mean values [range] 6 sem; reference values are in brackets.
a P , 0.05
b P , 0.005
be hypothesized that not only the locally produced ters in animal and human models [46, 47], whereas dis-
ruption of IGF-I results in severe impairment of boneIGFBP-4 and IGFBP-5 [4, 9, 44], but also their endocrine
levels may have significant biological effects on bone formation in mice and humans [48]. In our study, HD
patients with osteopenia showed lower levels of free and[15–18]. This view is supported by significant correlations
between bone histologic findings and serum levels of total IGF-I than patients without osteopenia according
to our and other previous findings in patients with os-bone markers and IGF system components. In this re-
gard, our findings demonstrate that in general, serum teopenia and osteoporosis [12, 13, 15]. Other investiga-
tors reported no correlations between circulating IGFslevels of stimulatory IGF system components show posi-
tive correlations with histologic parameters of bone for- and bone formation parameters in a smaller number of
predialysis [49] or dialysis patients [50]. A recent studymation, whereas the serum levels of inhibitory IGFBPs
(IGFBP-2 and IGFBP-4) show positive correlations with in 533 premenopausal and postmenopausal women in
whom bone biopsies from the iliac crest were obtainedhistologic indices of bone loss. Furthermore, we ob-
served that the bone marrow hematopoietic cell volume demonstrated that bone matrix IGF-I was positively as-
sociated with histomorphometric and biochemical pa-correlated positively with IGF-I, IGF-II, and IGFBP-6
levels but negatively with IGFBP-1. In the same patients, rameters of bone formation and with cancellous bone
volume [51]. These authors further reported that womenblood hemoglobin values showed significant positive cor-
relations with levels of free IGF-I (r 5 0.30, P , 0.05) with a bone matrix IGF-I concentration two standard
deviations above the mean had a 20% higher bone vol-and IGF-II (r 5 0.39, P , 0.05). Taken together, these
findings indicate that an imbalance between IGFs and ume than women with a bone matrix IGF-I concentration
two standard deviations below the mean and that serumIGFBPs (that is, decreased IGF bioavailability) may not
only contribute to bone loss but also to anemia in renal IGF-I was weakly associated with bone matrix IGF-I
when adjusted for the serum concentration of IGF bind-failure patients.
As a functional consequence, the imbalance in circu- ing protein-3. In this study, we found that serum levels
of stimulatory IGFBP-5 showed significant positive cor-lating IGF system components in uremia together with
a complex resistance to both growth hormone and IGF-I relations with cortical bone thickness, trabecular bone
volume, trabecular interconnections, and osteoblasticsignificantly contributes to growth failure in children and
experimental animals [34, 43, 45]. Our study provides surface (Fig. 5). This finding with IGFBP-5 is significant
for several reasons: (a) IGFBP-5, a growth hormoneevidence for an association between bone histology,
bone metabolic markers, and circulating levels of IGF dependent IGFBP, has been shown to stimulate bone
formation parameters both in vitro and in vivo [52]; (b)system components in renal osteodystrophy patients.
Previous studies support this hypothesis showing that IGFBP-5 actions in bone may involve both IGF-depen-
dent and IGF-independent mechanisms [7]; and (c)IGF-I administration stimulates bone formation parame-
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among the six high affinity IGFBPs, IGFBP-5 is the only ship between circulating IGF system components and
bone metabolism in patients with different forms of hy-IGFBP whose levels in serum were not influenced by
the stage of renal insufficiency (Table 2). perparathyroidism and renal osteodystrophy. The ele-
vated free IGF-I levels in early renal failure may com-It is well known that PTH can cause bone formation
[53] as well as bone loss [54]. The anabolic effects of pensate for the inhibitory IGFBP action, whereas in
ESRF, the predominant increase of inhibitory ratherPTH [53, 55] are at least partially mediated by an increase
in osteoblastic IGF-I synthesis, which inhibits apoptosis than stimulatory IGFBPs (Fig. 1) may diminish IGF bio-
activity. The major findings of this study support the ideaof osteoblast precursor cells. It is important to note that
the anabolic action of PTH involves its pulsatile secretion that especially the markedly elevated IGFBP-4 levels,
which are characteristic for CRF but not pHPT, and thepattern, which is disturbed in both advanced HPT and
CRF. An interesting finding of our study was that pHPT lower IGFBP-5 levels may contribute to a diminished
bone formation in renal osteodystrophy. The character-and CRF I8 patients showed similar elevations of both
PTH and free IGF-I, whereas in advanced renal failure, ization of circulating growth factors and cytokines may
not only elucidate the complex pathophysiology of renalIGF synthesis may not keep up with rising PTH. Consis-
tent with previous reports [28–32, 56], dialysis patients osteodystrophy [60], but also provide tools for the differ-
ential diagnosis and therapy.with low turnover osteopathy showed significantly lower
levels of PTH and B-ALP than patients with HTO. Our
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APPENDIXPTH, B-ALP, and OSC [56]. In our study, IGFBP-5
correlated positively with all histologic signs of bone Abbreviations used in this article are: B-ALP, bone alkaline phos-
phatase; CRF, chronic renal failure; CRF I8, mild renal insufficiency;formation and therefore might gain importance as a
CRF II8, moderate renal insufficiency; CRF III8, complex uremic syn-more specific marker of bone formation. The following drome; ESRF, end-stage renal failure; HD, hemodialysis; HTO, high
examples in HD patients (age-matched, no diabetes mel- bone turnover; IDDM, insulin-dependent diabetes mellitus; IGF, insu-
lin-like growth factor; IGFBP, insulin-like growth factor binding pro-litus) in whom bone markers (Table 1 and Table 2 show
tein; LTO, low bone turnover; OSC, osteocalcin; pHPT, primary hyper-reference values of bone markers) and bone histology parathyroidism; PD, peritoneal dialysis; PICP, procollagen type 1
were performed may support this hypothesis: (a) in two C-peptide; PTH, parathyroid hormone; RIA, radioimmunoassay; RTX,
renal transplantation; SDS-PAGE, sodium dodecyl sulfate-polyacryl-older patients (A/B; age, 61/62 years; dialysis duration,
amide gel electrophoresis; sHPT, secondary hyperparathyroidism.6/8 years) showing only slight differences in B-ALP (25/
23 ng/mL) and OSC (58/44 ng/mL) but different levels
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